Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease

被引:49
作者
van Dijk, AMC
Kessler, FL
Stadhouders-Keet, SAE
Verdonck, LF
de Gast, GC
Otten, HG
机构
[1] Univ Utrecht Hosp, Dept Immunohaematol, Jordan Lab, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht Hosp, Dept Dermatol, NL-3584 CX Utrecht, Netherlands
[3] Dutch Canc Inst, Div Med Oncol, Amsterdam, Netherlands
关键词
GVHD; prevention; minor histocompatibility antigen; T cells; alloreactivity;
D O I
10.1046/j.1365-2141.1999.01675.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Development of acute graft-versus-host disease (aGVHD) following HLA-identical sibling bone marrow transplantation (BMT) remains a serious complication. Aselective depletion of T cells has proved to be effective in preventing aGVHD but is associated with relapse and increased incidence of infection. As aGVHD is directed mainly against epithelial tissues we examined whether it would be feasible to selectively deplete T cells reactive with epithelial cells whilst preserving other specificities. Donor T cells which express HLA-DR, CD25, CD69 and CD71 activation markers after cocultivation with patient keratinocytes were depleted using magnetic cell separation techniques. Depletion of major as well as minor histocompatibility antigen activated T cells revealed a significant (P=0.004 and P=0.031, respectively) 10-fold decrease in the frequency of donor T lymphocyte precursors reactive with patient keratinocytes. The frequency reactive with third-party and patient peripheral blood mononuclear cells, including leukaemia cells, remained unchanged, supporting the notion that aGVHD and graft-versus-leukaemia (GVL) may be separable. This alloantigen-specific depletion may be used in matched unrelated as well as HLA-identical sibling BMT for reducing aGVHD whilst conserving GVL.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 28 条
[1]   Recent advances in graft-versus-host disease (GVHD) prevention [J].
Blazar, BR ;
Korngold, R ;
Vallera, DA .
IMMUNOLOGICAL REVIEWS, 1997, 157 :79-109
[2]  
Caruso A, 1997, CYTOMETRY, V27, P71, DOI 10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO
[3]  
2-O
[4]  
DEBUEGER M, 1992, J IMMUNOL, V149, P1788
[5]   The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism [J].
den Haan, JMM ;
Meadows, LM ;
Wang, W ;
Pool, J ;
Blokland, E ;
Bishop, TL ;
Reinhardus, C ;
Shabanowitz, J ;
Offringa, R ;
Hunt, DF ;
Engelhard, VH ;
Goulmy, E .
SCIENCE, 1998, 279 (5353) :1054-1057
[6]   Low-dose donor CD8(+) cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase [J].
Gallardo, D ;
GarciaLopez, J ;
Sureda, A ;
Canals, C ;
Ferra, C ;
Cancelas, JA ;
Berlanga, JJ ;
Brunet, S ;
Boque, C ;
Picon, M ;
Torrico, C ;
Amill, B ;
Martino, R ;
Martinez, C ;
MartinHenao, G ;
DomingoAlbos, A ;
Granena, A .
BONE MARROW TRANSPLANTATION, 1997, 20 (11) :945-952
[7]   Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool [J].
Gribben, JG ;
Guinan, EC ;
Boussiotis, VA ;
Ke, XY ;
Linsley, L ;
Sieff, C ;
Gray, GS ;
Freeman, GJ ;
Nadler, LM .
BLOOD, 1996, 87 (11) :4887-4893
[8]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[9]  
JANSEN J, 1995, LEUKEMIA, V9, P271
[10]   Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: Implications for separating graft-versus-leukemia effect from graft-versus-host disease [J].
Jiang, YZ ;
Mavroudis, DA ;
Dermime, S ;
Molldrem, J ;
Hensel, NF ;
Barrett, AJ .
BONE MARROW TRANSPLANTATION, 1997, 19 (09) :899-903